Rønning Torunn Gresdal, Enger Hege, Afset Jan Egil, Ås Christina Gabrielsen
The Norwegian MRSA Reference Laboratory, Department of Medical Microbiology, Clinic of Laboratory Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
JAC Antimicrob Resist. 2025 Jun 6;7(3):dlaf094. doi: 10.1093/jacamr/dlaf094. eCollection 2025 Jun.
The purpose of this study was to analyse nationwide trends in antimicrobial susceptibility and molecular epidemiology of all MRSA strains in Norway over a 10-year period.
All cases of MRSA in Norway from 2008 to 2017 were included, limited to the first case per year per individual ( = 15 200). Strains were confirmed as MRSA with PCR and genotyped using -typing. Antimicrobial susceptibility data and epidemiological data were collected from the Norwegian MRSA reference laboratory and the Norwegian Surveillance System for Communicable Diseases, respectively.
Despite an increase in MRSA cases, antimicrobial resistance rates remained stable throughout the study period. The most common susceptibility profile of the MRSA strains was resistance to cefoxitin alone (41.4%), while co-resistance (58.6%) was observed most commonly for erythromycin (31.0%), tetracycline (25.3%) and ciprofloxacin/norfloxacin (21.6%). Notably, associations were identified between specific resistance patterns and clinical variables, including higher resistance rates among healthcare-associated MRSA, particularly in older adults and nursing home residents. Geographic associations were also observed, linking specific resistance profiles to strains acquired in North America, Africa and Asia.
The findings highlight a complex landscape of MRSA resistance in a low-prevalence country, characterized by a diverse genotypic population and stable longitudinal trends in resistance rates. However, the prevalence of co-resistance to one or more antibiotics among Norwegian MRSA strains was high and increasing. This study thus underscores the importance of continuous surveillance and adherence to antimicrobial guidelines.
本研究旨在分析挪威10年间所有耐甲氧西林金黄色葡萄球菌(MRSA)菌株的全国抗菌药物敏感性趋势和分子流行病学情况。
纳入2008年至2017年挪威所有MRSA病例,限于每人每年的首例病例(共15200例)。通过聚合酶链反应(PCR)确认菌株为MRSA,并使用分型进行基因分型。抗菌药物敏感性数据和流行病学数据分别从挪威MRSA参考实验室和挪威传染病监测系统收集。
尽管MRSA病例有所增加,但在整个研究期间抗菌药物耐药率保持稳定。MRSA菌株最常见的药敏谱是仅对头孢西丁耐药(41.4%),而最常见的联合耐药(58.6%)是对红霉素(31.0%)、四环素(25.3%)和环丙沙星/诺氟沙星(21.6%)。值得注意的是,在特定耐药模式与临床变量之间发现了关联,包括医疗保健相关MRSA的耐药率较高,尤其是在老年人和养老院居民中。还观察到地理关联,将特定耐药谱与在北美、非洲和亚洲获得的菌株联系起来。
研究结果凸显了一个低流行国家中MRSA耐药的复杂情况,其特点是基因型群体多样且耐药率呈稳定的纵向趋势。然而,挪威MRSA菌株对一种或多种抗生素的联合耐药率很高且呈上升趋势。因此,本研究强调了持续监测和遵守抗菌指南的重要性。